Associations - FGFR3-TACC3 fusion

FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Gastric Cancer Gastric Cancer	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Gastric Cancer Gastric Cancer	TAS 120 Sensitive: C3 – Early Trials Cancer Discov - 4 weeks	TAS 120 Sensitive: C3 – Early Trials Cancer Discov - 4 weeks
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Glioblastoma GBM	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Glioblastoma GBM	anlotinib Sensitive: C3 – Early Trials	anlotinib Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	infigratinib Sensitive: C3 – Early Trials	infigratinib Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	Debio 1347 Sensitive: C3 – Early Trials	Debio 1347 Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Glioblastoma GBM	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Glioblastoma GBM	erdafitinib Sensitive: C3 – Early Trials	erdafitinib Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Non Small Cell Lung Cancer NSCLC	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Non Small Cell Lung Cancer NSCLC	infigratinib Sensitive: C3 – Early Trials	infigratinib Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Non Small Cell Lung Cancer NSCLC	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Non Small Cell Lung Cancer NSCLC	ponatinib Sensitive: C3 – Early Trials	ponatinib Sensitive: C3 – Early Trials
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Glioma Glioma	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Glioma Glioma	anlotinib Sensitive: C4 – Case Studies	anlotinib Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Endometrial Cancer Endometrial Cancer	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Endometrial Cancer Endometrial Cancer	erdafitinib Sensitive: C4 – Case Studies	erdafitinib Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Bladder Cancer Bladder Cancer	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Bladder Cancer Bladder Cancer	erdafitinib Sensitive: C4 – Case Studies	erdafitinib Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	atezolizumab Sensitive: C4 – Case Studies	atezolizumab Sensitive: C4 – Case Studies
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	erdafitinib Sensitive: D – Preclinical	erdafitinib Sensitive: D – Preclinical
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Bladder Cancer Bladder Cancer	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Bladder Cancer Bladder Cancer	MPT0L145 Sensitive: D – Preclinical	MPT0L145 Sensitive: D – Preclinical
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Cholangiocarcinoma Cholangiocarcinoma	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Cholangiocarcinoma Cholangiocarcinoma	infigratinib Sensitive: D – Preclinical	infigratinib Sensitive: D – Preclinical
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Urothelial Cancer Urothelial Cancer	dasatinib + infigratinib Sensitive: D – Preclinical	dasatinib + infigratinib Sensitive: D – Preclinical